New generation DES present better results in vein grafts than older DES and BMS

There is little information comparing contemporary drug eluting stents (DES)  against bare metal stents (BMS), for PCI in saphenous vein grafts in patients receiving (CABG).

 New Generation DES Present Better Results in Vein Grafts than Older DES and BMS

This study aimed to assess clinical outcomes after PCI in saphenous vein grafts in patients receiving BMS, first generation DES, and new generation DES between 2006 and 2013. The study included inhospital events, and 30 day and one year mortality rates.

 

A total 15,003 patients received PCI in saphenous vein grafts during this period: 38% received BMS, 15% received first generation DES and 47% new generation DES.

 

Inhospital major adverse cardiovascular events was significantly lower in patients treated with new generation DES (OR, 0.51; CI 95%, 0.38–0.68; p<0.001) compared to those receiving older DES or BMS.


Also Read: “Second Generation DES Present Lower Mortality in Saphenous Vein Graft Lesions”.


 Similarly, 30 day (OR, 0.43; CI 95%, 0.32–0.59; p<0.001) and one year mortality (OR, 0.60; CI 95%, 0.51–0.71; p<0.001) were lower with new generation DES.

 

Conclusion

Patients receiving new generation DES in saphenous vein grafts present lower inhospital adverse events rate, and lower 30 day and one year mortality compared to first generation DES and BMS.

 

Editorial Comment

A significant number of vein grafts (10-40%) will be occluded in the first year and this will inexorable continue at a 2-5% annual rate, which accelerates as time goes by. The risk of reintervention and the technical difficulty to treat the native artery makes it necessary to treat vein grafts with PCI (it might even reach 10% of cases).

 

Several factors make this territory more challenging for PCI and there is no doubt that this disease is far more aggressive in vein grafts than in native arteries. This difficulty, however, does not affect the choice of device: new generation DES are also better in this territory.

 

Original title: Choice of Stent for Percutaneous Coronary Intervention of Saphenous Vein Grafts.

Reference: Javaid Iqbal et al. Circ Cardiovasc Interv. 2017;10:e004457.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....